Innovation is at the heart of medical and pharmaceutical advancement. FDA provides specialized pathways and programs to support products that may offer meaningful improvements in safety, effectiveness, diagnosis, treatment, or patient care. Whether your product may qualify as breakthrough, novel, or eligible for an explored pathway, the right regulatory strategy is essential. Our consultants help you assess your product's potential, identify the appropriate FDA pathway, and build a clear strategy to move innovation forward responsibly and efficiently.

​

• The FDA often categorizes innovative products into two broad categories: "breakthrough" and "novel."

• A breakthrough product is one that provides a substantial improvement in the treatment, diagnosis, or prevention of a serious or life-threatening disease or condition. To be considered a breakthrough, a product must demonstrate preliminary clinical evidence indicating that it may offer substantial improvement over existing therapies.

• A novel product, on the other hand, is one that is substantially different from any other product previously approved by the FDA. Novel products may be approved through a variety of regulatory pathways, such as the FDA's Expedited Programs, which are designed to accelerate the development and review of drugs and biologics for serious conditions.

• Overall, the FDA encourages and supports innovative product development that can improve patient care and advance public health.